Overall survival ‐ Gemcitabine plus topoisomerase inhibitor · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus taxane · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus other combinations of chemotherapy · advanced pancreatic cancer
Gemcitabine combinations may leads to lower overall survival ‐ Gemcitabine plus other combinations of chemotherapy compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus other agent(s) · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus platinum agent · advanced pancreatic cancer
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
1 finding from 1 review
Overall survival ‐ Gemcitabine plus fluoropyrimidine · advanced pancreatic cancer
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
1 finding from 1 review
Time to recurrence · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in time to recurrence (absolute effect size estimates based on… compared with saline (low certainty).
1 finding from 1 review
Grade III–V adverse events (local adverse events which result in delay intravesical treatment were regarded as Grade III–V complications) · patients with non‐muscle invasive bladder cancer
It is very uncertain whether gemcitabine changes grade III–V adverse events (local adverse events which result in… compared with mitomycin (very low certainty).
1 finding from 1 review
Time to death from bladder cancer · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to death from any cause · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade I or II adverse events (local adverse events which did not result in delay intravesical treatment) · patients with non‐muscle invasive bladder cancer
Gemcitabine may leads to lower grade I or II adverse events (local adverse events which did not… compared with mitomycin (low certainty).
1 finding from 1 review
Disease‐specific quality of life · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
Gemcitabine may leads to lower time to recurrence compared with BCG (low certainty).
1 finding from 1 review
Time to progression · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
Gemcitabine may leads to lower time to progression compared with BCG (low certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade III–V adverse events compared with BCG (very low certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes time to death from bladder cancer compared with BCG (very low certainty).
1 finding from 1 review
Time to death from any cause · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression · patients with non‐muscle invasive bladder cancer
Gemcitabine showed no clear difference in time to progression (absolute effect size estimates based on… compared with saline (low certainty).
1 finding from 1 review
Adverse events: grade 1 to 2 · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade I or II adverse events compared with BCG (very low certainty).
1 finding from 1 review
Disease‐specific quality of life · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found